ライフサイエンスコーパス: hematopoietic cell

1 ne kinase (Btk) is expressed in a variety of hematopoietic cells.

2 entiation of normal and/or malignant myeloid hematopoietic cells.

3 ice upon conditional inactivation of Atg5 in hematopoietic cells.

4 , and GNB5) in HL60 cells and primary murine hematopoietic cells.

5 for dynamically regulating output of mature hematopoietic cells.

6 hway and as a response to HDACi in malignant hematopoietic cells.

7 ied in a short period with rapid decrease of hematopoietic cells.

8 smooth muscles cells, epithelial cells, and hematopoietic cells.

9 f cell surface proteins largely expressed in hematopoietic cells.

10 oliferate and rapidly regenerate compromised hematopoietic cells.

11 els are detected on healthy B cells or other hematopoietic cells.

12 utant that lacks most endothelial as well as hematopoietic cells.

13 and impaired lysosomal vesicles formation in hematopoietic cells.

14 nts, but only require functional TLRs in the hematopoietic cells.

15 ating protein that is expressed primarily in hematopoietic cells.

16 nscriptional activity and protein binding in hematopoietic cells.

17 d a significant increase of proliferation in hematopoietic cells.

18 ulatory molecule constitutively expressed on hematopoietic cells.

19 nd AML-in an inducible, hemizygous manner in hematopoietic cells.

20 creased proliferative potential of aneuploid hematopoietic cells.

21 d the Rad18 and FA pathways are separable in hematopoietic cells.

22 esis pathway expression compared with normal hematopoietic cells.

23 minant of HCMV tropism for select subsets of hematopoietic cells.

24 mage, is compromised in Foxo3(-/-) primitive hematopoietic cells.

25 ase Atad3a hyperactivated mitophagy in mouse hematopoietic cells.

26 increased frequency of somatic mutations in hematopoietic cells.

27 lasma viremia but not the number of infected hematopoietic cells.

28 romal network, which maintains and regulates hematopoietic cells.

29 and accelerated recovery of host vessels and hematopoietic cells.

30 In these models, Nf1 haploinsufficiency in hematopoietic cells accelerated tumor onset and increase

31 Here we found that donor hematopoietic cells act on sinusoidal endothelial cells

32 ts of these methods for normal and malignant hematopoietic cells analyzed by mass cytometry and provi

33 safely induces immune tolerance to combined hematopoietic cell and organ allografts in humans.

34 immune diseases, as well as after allogeneic hematopoietic cell and solid organ transplantation.

35 ern of splicing in primary patient and mouse hematopoietic cells and alter hematopoietic differentiat

36 e activating kinase mutations in circulating hematopoietic cells and bone marrow-based hematopoietic

37 nt understanding of the interactions between hematopoietic cells and bone marrow/thymic niches during

38 Nascent CD34(+) hematopoietic cells and corresponding cells sorted from

39 ne marrow (BM) is a reservoir for immune and hematopoietic cells and critical for tissue repair and r

40 -/-) mice have decreased MHC-I expression on hematopoietic cells and fewer CD8(+) T cells prior to in

41 pends upon DNase II deficiency in both donor hematopoietic cells and host radioresistant cells.

42 m cells were educated by HLA from both donor hematopoietic cells and host stromal cells.

43 ich Nup98 promotes gene activation in normal hematopoietic cells and how that process is altered by t

44 ppressor, which regulates the homeostasis of hematopoietic cells and immune responses.

45 iosensor constructs for facile expression in hematopoietic cells and performed functional validations

46 affect the composition of tumor-infiltrating hematopoietic cells and subsequent tumor progression.

47 in LNK/SH2B3, which in mice is expressed in hematopoietic cells and suppresses thrombopoietin signal

48 n and discuss how immune communications with hematopoietic cells and the microbiota orchestrate local

49 also induced increased FAO and OXPHOS in non-hematopoietic cells and were found to be responsible for

50 esis (enterocytes, hepatocytes, macrophages, hematopoietic cells, and in the case of pregnancy, place

51 e is expressed in many cell types, including hematopoietic cells, and is a member of the Tec kinase f

52 AGMO is expressed in hematopoietic cells, and is strongly expressed in the li

53 to the expansion and eventual exhaustion of hematopoietic cells, and this occurs in the face of lowe

54 ting cell-free DNA is primarily derived from hematopoietic cells, and we surmised that the malignant

55 king Kif5b (the heavy chain of kinesin-1) in hematopoietic cells are less sensitive to IgE-mediated,

56 r or related progenitors for endothelial and hematopoietic cells are present during organogenesis is

57 sly reported findings with MerTK deficiency, hematopoietic cell-Axl deficiency in WD-fed Ldlr(-/-) mi

58 Human hematopoietic cells bearing mutations in combinations of

59 Following the prenatal transfer of fetal hematopoietic cells between age-matched allogeneic murin

60 MPL is required for mutant CALR to transform hematopoietic cells; binding alone is insufficient for c

61 EphrinB2 silencing impairs ES generation of hematopoietic cells but not generation of endothelial ce

62 andidate is L-plastin, normally expressed in hematopoietic cells, but considered a common marker of m

63 NK cells that was induced by MHC I-deficient hematopoietic cells, but not the tolerance induced by MH

64 e effects of conditional deletion of Pten in hematopoietic cells by crossing Pten conditional knockou

65 Engraftment of human hematopoietic cells can be evaluated by flow cytometry 8

66 Human hematopoietic cells can subsequently be transplanted dir

67 ing osteoprogenitors and host-derived mature hematopoietic cells, clonogenic lineage-committed progen

68 s study, we show that Nod1 expression in the hematopoietic cell compartment is critical for limiting

69 we show that JAK2-V617F and loss of Ezh2 in hematopoietic cells contribute synergistically to the de

70 Hematopoietic cells contribute to this microenvironment,

71 we showed that the transfer of IFN-competent hematopoietic cells controlled HSV-1 replication and dam

72 lymphoid and myeloid cells, consistent with hematopoietic cell death as the normal source of cfDNA.

73 Depletion of Gram-negative microbiota, hematopoietic cell deletion of Toll-like receptor 4 (TLR

74 Loss of CD16, hematopoietic cell-derived BAFF, or blocking IC:FcgammaR

75 We show that mice with deletion of Gpx4 in hematopoietic cells develop anemia and that Gpx4 is esse

76 veals that KDM2B is an important mediator of hematopoietic cell development and has opposing roles in

77 Hematopoietic cell development was also largely unaffect

78 ork from Velten et al. (2017) now shows that hematopoietic cells differentiate via a mechanism of con

79 HSCs but does not affect in vitro or in vivo hematopoietic cell differentiation.

80 Split thickness skin grafts from the hematopoietic cell donor swine were placed on recipients

81 tingly, Ptch2 loss in either the niche or in hematopoietic cells dramatically accelerated human JAK2V

82 ligands cutaneous lymphocyte Ag, CD43E, and hematopoietic cell E-selectin/L-selectin ligand, respect

83 significantly affect risk for chronic GVHD, hematopoietic cell engraftment, overall mortality, or no

84 nts of the medium required to grow zebrafish hematopoietic cells ex vivo.

85 PHD2]; Egln1(Tie2)) in endothelial cells and hematopoietic cells exhibited spontaneous severe PAH wit

86 Hematopoietic cells expressing the hypermorphic Rad50(s)

87 which is unresponsive to transplant due to a hematopoietic cell-extrinsic mechanism.

88 pectedly, in WT hosts, donor MHC I-deficient hematopoietic cells failed to induce hyporesponsiveness

89 etic mechanism supporting the maintenance of hematopoietic cell fate via DNA methylation-mediated per

90 ollicles, adipocytes, endothelial cells, and hematopoietic cells for adipogenesis.

91 been considered the continuous source of all hematopoietic cells for the life of an individual.

92 e substantially greater in baboons receiving hematopoietic cells from a pig expressing high levels of

93 luidic CTC-iChip, which efficiently depletes hematopoietic cells from blood specimens and enriches fo

94 Additionally, we examined the phenotypes of hematopoietic cells from Ctsg-PML-RARA mice, which expre

95 Here, we reconstituted mice with human hematopoietic cells from donors with homozygous KIR liga

96 ogic reactivation of fetal hemoglobin (HbF), hematopoietic cells from patients with SCD were treated

97 with homozygous KIR ligands or with a mix of hematopoietic cells from these homozygous donors, allowi

98 hat myeloperoxidase inhibition could protect hematopoietic cells from TOP2 poison-mediated genotoxic

99 Mobilized peripheral blood hematopoietic cells from transgenic swine expressing hig

100 e, we have transcriptionally profiled single hematopoietic cells from zebrafish to define erythroid,

101 mice, restriction of hTetherin expression to hematopoietic cells gave apparently healthy mice.

102 Here, we show that hematopoietic cells grown in culture shed exosome-like E

103 The expression of hTetherin in hematopoietic cells had little or no effect on the numbe

104 We find that both normal and malignant hematopoietic cells harbor an intact clock with robust c

105 However, RAS activation in hematopoietic cells has immunologic effects that diverge

106 e the important role that MAVS expression in hematopoietic cells has in regulating the inflammatory r

107 nervous system-bone marrow communication in hematopoietic cell homeostasis and their impact on hyper

108 mor-dependent changes to bone marrow-derived hematopoietic cells impact TNBC progression.

109 Finally, silencing Rev7 in primary hematopoietic cells impaired progenitor function, sugges

110 ingly little is known, however, about mature hematopoietic cells in AF, which could potentially be in

111 demonstrate a major role of both stromal and hematopoietic cells in all aspects of DNA-driven autoimm

112 the absence of ATMIN would affect primitive hematopoietic cells in an ATM-dependent or -independent

113 ults demonstrate a critical role for MAVS in hematopoietic cells in augmenting the kinetics of WNV cl

114 tients, but shows minimal toxicity to normal hematopoietic cells in mice as well as red blood cells a

115 itional deletion of Bmal1 in endothelium and hematopoietic cells in murine models of microvascular an

116 contribution of TLR2 on nonhematopoietic and hematopoietic cells in resistance against chronic M. tub

117 Total body irradiation (TBI) damages hematopoietic cells in the bone marrow and thymus; howev

118 fferentially interacts with murine and human hematopoietic cells in these mouse models and how these

119 ced a gain of function, transforming primary hematopoietic cells in vitro and in transplantation assa

120 significantly less-severe effects on non-CML hematopoietic cells in vitro and in vivo.

121 ivascular endothelial properties that expand hematopoietic cells in vitro.

122 Immunophenotyping of hematopoietic cells in wild-type versus knockout livers

123 , with wild-type (WT) and/or MHC I-deficient hematopoietic cells in WT or MHC I-deficient C57BL/6 hos

124 equired TLR4 signaling predominantly in lung hematopoietic cells, including CD11c(+) cells.

125 o be mediated, in part, by TLR4 expressed on hematopoietic cells, including macrophages.

126 ) is a signaling adaptor expressed in mature hematopoietic cells, including monocytes and neutrophils

127 In hematopoietic cells, including neutrophils, Munc13-4 reg

128 if (ITAM)-containing receptors in almost all hematopoietic cells, including platelets.

129 These studies revealed that many hematopoietic cells, including subsets of monocytes, mac

130 1(-) but HLA-B*07:02(+) nonhematopoietic and hematopoietic cells indicated no off-target toxicity.

131 rrent Tet2 loss and Nras(G12D) expression in hematopoietic cells induced myeloid transformation, with

132 focused on the molecular mechanisms by which hematopoietic cells initiate and maintain innate and ada

133 Thus, activation of NLRP3 in hematopoietic cells initiates IL-1beta-driven paracrine

134 Further, we explore the case for stromal-hematopoietic cell interactions contributing to neoplast

135 a mechanism by which mutated MSPCs transform hematopoietic cells into a malignant-prone state.

136 RIG-I-like receptor RNA-sensing pathway, in hematopoietic cells is critical for protection from leth

137 analyses suggest that CD70 expressed by host hematopoietic cells is involved in the control of allore

138 show that expression of functional Panx1 in hematopoietic cells is necessary for mechanical hypersen

139 Here, we show that Pannexin 1 (Panx1) in hematopoietic cells is required for pain-like responses

140 udies demonstrated that IL-1beta produced by hematopoietic cells is sensed by the radioresistant comp

141 Ectopic overexpression of dnmt3bb.1 in non-hematopoietic cells is sufficient to methylate the cmyb

142 istomorphological analyses and the number of hematopoietic cells isolated within ossicles.

143 to analyzing single cells from two types of hematopoietic cells, K562 and GM12878 and small populati

144 s, as well as primary WM cells show enhanced hematopoietic cell kinase (HCK) transcription and activa

145 Aberrant activation of the SRC family kinase hematopoietic cell kinase (HCK) triggers hematological m

146 We identified an Src family tyrosine kinase, hematopoietic cell kinase (Hck), as upregulated in allog

147 In human CD34(+) hematopoietic cells, knockdown of CXCL4 or pharmacologic

148 d previous studies have shown that mice with hematopoietic cells lacking Atg7 develop an MDS-like syn

149 elopment, which give rise to endothelial and hematopoietic cell lineages.

150 xpression on splenic monocytes, whereas many hematopoietic cell lines brightly display Clr-g.

151 roughout different leukocyte populations and hematopoietic cell lines.

152 cytotoxic agents in C57BL/6 mice in vivo and hematopoietic cell lines.

153 ut system and found that MOF is critical for hematopoietic cell maintenance and HSC engraftment capac

154 n, and cells positive for CD45, considered a hematopoietic cell marker.

155 We used both an experimental hematopoietic cell model of latency and cells from natur

156 Here we show that in hematopoietic cells, Nup98 binds predominantly to transc

157 Here we report that the deletion of Th in hematopoietic cells of adult mice neither alters energy

158 gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice.

159 ypes could be complemented by wild-type (WT) hematopoietic cells or administration of exosomes produc

160 rcomas revealed infiltrating myeloid-derived hematopoietic cells, particularly macrophages and neutro

161 trol of EBV infection, indicating that mixed hematopoietic cell populations could be exploited to imp

162 the development of novel therapies engaging hematopoietic cell populations with previously unrecogni

163 at the expression of ARPC1B is restricted to hematopoietic cells, potentially explaining why a mutati

164 has been a long-sought-after goal for use in hematopoietic cell production, disease modeling, and eve

165 Recent data suggest that mature hematopoietic cells regulate BM stromal-cell function.

166 t an internalizing immunotoxin targeting the hematopoietic-cell-restricted CD45 receptor that effecti

167 Here, we show that a deficiency of MAVS in hematopoietic cells resulted in increased mortality and

168 model, we found that tetherin expression on hematopoietic cells resulted in the specific reduction o

169 pecific deletion of BMAL1 in endothelial and hematopoietic cells results in phenotypic features simil

170 ted by RIPK1, RIPK3, and MLKL kinases but in hematopoietic cells RIPK1 has anti-inflammatory roles an

171 eric mice reconstituted with NLRP3-deficient hematopoietic cells showed that NLRP3 in immune cells me

172 Mice with a hematopoietic cell-specific deletion of G9a (Vav.G9a(-/-

173 specific antibodies against OSM, GM-CSF, and hematopoietic cell-specific markers.

174 Hematopoietic cell-specific PTPN22 encodes lymphoid phos

175 Despite the 92% homology of the hematopoietic cell-specific Rac2 to the canonical isofor

176 f a pre-metastatic niche that is composed of hematopoietic cells, stromal cells and extracellular mat

177 study, we observed continuous multi-lineage hematopoietic cell supply in peripheral blood from Krt7-

178 aros targets, including CTNND1 and the early hematopoietic cell surface marker CD34, resulted in redu

179 igen by flow cytometry together with various hematopoietic cell surface markers.

180 ress response and, specifically, Smarcal1 in hematopoietic cell survival and tumor development.

181 ing oral homeostasis, whereas its absence in hematopoietic cells synergized the level of dysbiosis.

182 stem cells, but not in normal CD34(+)CD38(-) hematopoietic cells, T cells, or vital tissues.

183 ofile of gene expression during infection in hematopoietic cells than previously appreciated.

184 emic potential, but when differentiated into hematopoietic cells, they reacquired the ability to give

185 of RNA-binding proteins that are specific to hematopoietic cells, thus unraveling potential regulator

186 e experiments, to exclude gene extinction in hematopoietic cells, Tie2-Cre/LoxP-PTP1B mice were letha

187 Tumors are capable of coopting hematopoietic cells to create a suitable microenvironmen

188 UNX1 is directly involved in the response of hematopoietic cells to cytotoxic agents.

189 losis killing but rather to function through hematopoietic cells to reduce M. tuberculosis-elicited i

190 Chemoattractant-mediated recruitment of hematopoietic cells to sites of pathogen growth or tissu

191 ons in the embryo during endothelial cell to hematopoietic cell transition to affect hematopoietic cl

192 Autologous hematopoietic cell transplant (AHCT) for HIV-infected pa

193 The ability to distinguish allogeneic hematopoietic cell transplant (allo-HCT) recipients at r

194 s obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly uni

195 integrated human herpesvirus 6 (ciHHV-6) in hematopoietic cell transplant (HCT) donors or recipients

196 Records of solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients at a sing

197 and preventing disseminated viral disease in hematopoietic cell transplant (HCT) recipients but does

198 chromosomally integrated HHV-6 (iciHHV-6) in hematopoietic cell transplant (HCT) recipients is unclea

199 virus (RSV) treatment trials are lacking for hematopoietic cell transplant (HCT) recipients.

200 is associated with significant mortality in hematopoietic cell transplant (HCT) recipients.

201 ients with relapsed CLL following allogeneic hematopoietic cell transplant (HCT) who subsequently rec

202 hylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initia

203 cute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.

204 The majority of patients in need of a hematopoietic-cell transplant do not have a matched rela

205 syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blo

206 Allogeneic hematopoietic cell transplantation (allo-HCT) is a poten

207 immune reconstitution (IR) after allogeneic hematopoietic cell transplantation (allo-HCT) is highly

208 Allogeneic hematopoietic cell transplantation (allo-HCT) is indicat

209 life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT).

210 which is the main complication of allogeneic hematopoietic cell transplantation (allo-HCT).

211 sus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT).

212 Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using pos

213 tranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by

214 Viral reactivations (VRs) after hematopoietic cell transplantation (HCT) contribute to s

215 We analyzed patients treated with allogeneic hematopoietic cell transplantation (HCT) from 2010 to 20

216 st disease (GVHD) is higher after allogeneic hematopoietic cell transplantation (HCT) from unrelated

217 Hematopoietic cell transplantation (HCT) has been consid

218 Hematopoietic cell transplantation (HCT) has now been sh

219 intensity treatments and complications after hematopoietic cell transplantation (HCT) injure normal t

220 Hematopoietic cell transplantation (HCT) is a critical t

221 Hematopoietic cell transplantation (HCT) is curative for

222 optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown.

223 prophylaxis after matched-related allogeneic hematopoietic cell transplantation (HCT) recently showed

224 ) infection is a significant complication in hematopoietic cell transplantation (HCT) recipients.

225 Allogeneic hematopoietic cell transplantation (HCT) represents a po

226 e the risks of serious health outcomes among hematopoietic cell transplantation (HCT) survivors versu

227 nderwent myeloablative HLA-matched unrelated hematopoietic cell transplantation (HCT) were randomly a

228 uced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) with alemtuzuma

229 s received total body irradiation (4.5 cGy), hematopoietic cell transplantation (HCT), either marrow

230 etic stem cell (HSC) homing is important for hematopoietic cell transplantation (HCT), especially whe

231 ce and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT), NK cells deriv

232 After hematopoietic cell transplantation (HCT), polyoma-BK vir

233 When considering HLA-matched hematopoietic cell transplantation (HCT), sibling and un

234 ith hematologic malignancies cannot tolerate hematopoietic cell transplantation (HCT), whereas others

235 logy) in treatment algorithms for allogeneic hematopoietic cell transplantation (HCT), which implies

236 Both children required allogeneic hematopoietic cell transplantation (HCT), which resolved

237 outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT).

238 morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT).

239 tients undergoing cytotoxic chemotherapy and hematopoietic cell transplantation (HCT).

240 metabolism in response to alloantigens after hematopoietic cell transplantation (HCT).

241 st disease (GVHD) is common after allogeneic hematopoietic cell transplantation (HCT).

242 ll-recognized after myeloablative allogeneic hematopoietic cell transplantation (HCT).

243 Ss) are life-threatening complications after hematopoietic cell transplantation (HCT).

244 educed-intensity conditioning, related donor hematopoietic cell transplantation (HCT).

245 In utero hematopoietic cell transplantation (IUHCT) is a novel no

246 ptions for relapsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo-HCT) and t

247 eady-state and stressful conditions, such as hematopoietic cell transplantation and G-CSF- or inflamm

248 n adoptively transferred in murine models of hematopoietic cell transplantation and in phase 1/2 clin

249 The results of hematopoietic cell transplantation are analyzed, and rec

250 formation in a model that simulates clinical hematopoietic cell transplantation by transplanting MHC-

251 depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents

252 w (BM) vs peripheral blood (PB) (N = 551) in hematopoietic cell transplantation for hematologic neopl

253 s of the consortium describe the outcomes of hematopoietic cell transplantation for SCID during 2000-

254 Solid organ and allogeneic hematopoietic cell transplantation have become standard

255 ajor barrier to successful use of allogeneic hematopoietic cell transplantation is acute graft-versus

256 Hematopoietic cell transplantation is, to date, the only

257 mide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of p

258 e phenotype of chronic GVHD after allogeneic hematopoietic cell transplantation, characterized by fib

259 nt opportunistic pathogen in solid organ and hematopoietic cell transplantation, particularly in lung

260 ncluding those already incorporated into the hematopoietic cell transplantation-comorbidity index (HC

261 ablation is commonly used in solid organ and hematopoietic cell transplantation.

262 -versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation.

263 ficant obstacle to the success of allogeneic hematopoietic cell transplantation.

264 m of graft-versus-host interaction following hematopoietic cell transplantation.

265 ietic stem cells (HSCs) during an allogeneic hematopoietic cell transplantation.

266 myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation.

267 Interventions: Unrelated donor BM or PB hematopoietic cell transplantation.

268 in human and murine T cells after allogeneic hematopoietic cell transplantation.

269 uction syndrome, an early complication after hematopoietic cell transplantation.

270 major nonrelapse complication of allogeneic hematopoietic cell transplantation.

271 of morbidity and mortality after allogeneic hematopoietic cell transplantation.

272 e major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relaps

273 inib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known.

274 agement decisions could reduce the number of hematopoietic cell transplants in patients with AML by 2

275 idney transplants in 3 medical centers using hematopoietic cell transplants to establish mixed or com

276 lines by the Geuvadis consortium and for 38 hematopoietic cell types by the Differentiation Map Port

277 -Class to analyze 32 datasets from different hematopoietic cell types from the Blueprint Epigenome pr

278 elicit directly in the most primitive human hematopoietic cell types to promote their survival and p

279 The generation of distinct hematopoietic cell types, including tissue-resident immu

280 Through transcriptome profiling in 17 hematopoietic cell types, we found that ncRNAs expressed

281 intenance to a different extent in different hematopoietic cell types, with ploidy most severely pert

282 ions of 31,253 promoters in 17 human primary hematopoietic cell types.

283 fb-MYH11 fusion gene and deactivated Chd7 in hematopoietic cells upon inducing Cre with polyinosinic-

284 ore, expression of T89A LPL in LPL-deficient hematopoietic cells, using bone marrow chimeras, failed

285 ation, and suggest that tolerance induced by hematopoietic cells versus nonhematopoietic cells may be

286 Differential labeling of hematopoietic cells via intrabronchial and intravenous a

287 ow chimeras revealed that TLR4 expression on hematopoietic cells was necessary for oral tolerance ind

288 of phenotypically corrected, patient-derived hematopoietic cells was observed after transplantation w

289 RA in nonhematopoietic cells, but not in the hematopoietic cells, was required for the development of

290 transcriptomic and metabolomic profiling of hematopoietic cells, we reveal that EVI1 overexpression

291 cacy, we found that TET2 and cohesin-mutated hematopoietic cells were sensitive to azacitidine treatm

292 Stromal, but not hematopoietic, cells were the essential source of Notch

293 The Y chromosome is frequently lost in hematopoietic cells, which represents the most common so

294 stence relies on the successful infection of hematopoietic cells, which serve as sites of viral persi

295 Non-leukemic hematopoietic cells with DNMT3A(R882H) displayed focal m

296 Treatment of isolated hematopoietic cells with EVs did not affect their recept

297 of WNT and ACTIVIN signaling yields CD34(+) hematopoietic cells with HOXA expression that more close

298 t ZIKV infection was particularly evident in hematopoietic cells with microglia, the brain-resident m

299 ease present in inflammatory neutrophils and hematopoietic cells within the bone marrow microenvironm

300 Constitutive activation of beta-catenin in hematopoietic cells yielded lethal myeloid disease in a